Targeting of the C-Type Lectin Receptor Langerin Using Bifunctional Mannosylated Antigens
Copyright © 2020 Li, Hogervorst, Achilli, Bruijns, Spiekstra, Vivès, Thépaut, Filippov, van der Marel, van Vliet, Fieschi, Codée and van Kooyk..
Langerhans cells (LCs) are antigen-presenting cells that reside in the skin. They uniquely express high levels of the C-type lectin receptor Langerin (CD207), which is an attractive target for antigen delivery in immunotherapeutic vaccination strategies against cancer. We here assess a library of 20 synthetic, well-defined mannoside clusters, built up from one, two, and three of six monomannosides, dimannosides, or trimannosides, appended to an oligopeptide backbone, for binding with Langerin using surface plasmon resonance and flow cytometric quantification. It is found that Langerin binding affinity increases with increasing number of mannosides. Hexavalent presentation of the mannosides resulted in binding affinities ranging from 3 to 12 μM. Trivalent presentation of the dimannosides and trimannosides led to Langerin affinity in the same range. The model melanoma gp100 antigenic peptide was subsequently equipped with a hexavalent cluster of the dimannosides and trimannosides as targeting moieties. Surprisingly, although the bifunctional conjugates were taken up in LCs in a Langerin-dependent manner, limited antigen presentation to cytotoxic T cells was observed. These results indicate that targeting glycan moieties on immunotherapeutic vaccines should not only be validated for target binding, but also on the continued effects on biology, such as antigen presentation to both CD8+ and CD4+ T cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Frontiers in cell and developmental biology - 8(2020) vom: 08., Seite 556 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Rui-Jun Eveline [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dendritc cell |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fcell.2020.00556 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313358311 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313358311 | ||
| 003 | DE-627 | ||
| 005 | 20231225150413.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fcell.2020.00556 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1044.xml |
| 035 | |a (DE-627)NLM313358311 | ||
| 035 | |a (NLM)32760719 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Rui-Jun Eveline |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting of the C-Type Lectin Receptor Langerin Using Bifunctional Mannosylated Antigens |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020 Li, Hogervorst, Achilli, Bruijns, Spiekstra, Vivès, Thépaut, Filippov, van der Marel, van Vliet, Fieschi, Codée and van Kooyk. | ||
| 520 | |a Langerhans cells (LCs) are antigen-presenting cells that reside in the skin. They uniquely express high levels of the C-type lectin receptor Langerin (CD207), which is an attractive target for antigen delivery in immunotherapeutic vaccination strategies against cancer. We here assess a library of 20 synthetic, well-defined mannoside clusters, built up from one, two, and three of six monomannosides, dimannosides, or trimannosides, appended to an oligopeptide backbone, for binding with Langerin using surface plasmon resonance and flow cytometric quantification. It is found that Langerin binding affinity increases with increasing number of mannosides. Hexavalent presentation of the mannosides resulted in binding affinities ranging from 3 to 12 μM. Trivalent presentation of the dimannosides and trimannosides led to Langerin affinity in the same range. The model melanoma gp100 antigenic peptide was subsequently equipped with a hexavalent cluster of the dimannosides and trimannosides as targeting moieties. Surprisingly, although the bifunctional conjugates were taken up in LCs in a Langerin-dependent manner, limited antigen presentation to cytotoxic T cells was observed. These results indicate that targeting glycan moieties on immunotherapeutic vaccines should not only be validated for target binding, but also on the continued effects on biology, such as antigen presentation to both CD8+ and CD4+ T cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Langerhans cell | |
| 650 | 4 | |a dendritc cell | |
| 650 | 4 | |a glyco-antigen | |
| 650 | 4 | |a langerin | |
| 650 | 4 | |a mannoside | |
| 650 | 4 | |a peptide conjugate | |
| 650 | 4 | |a tumor associated antigens | |
| 650 | 4 | |a vaccine model | |
| 700 | 1 | |a Hogervorst, Tim P |e verfasserin |4 aut | |
| 700 | 1 | |a Achilli, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Bruijns, Sven C M |e verfasserin |4 aut | |
| 700 | 1 | |a Spiekstra, Sander |e verfasserin |4 aut | |
| 700 | 1 | |a Vivès, Corinne |e verfasserin |4 aut | |
| 700 | 1 | |a Thépaut, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Filippov, Dmitri V |e verfasserin |4 aut | |
| 700 | 1 | |a van der Marel, Gijs A |e verfasserin |4 aut | |
| 700 | 1 | |a van Vliet, Sandra J |e verfasserin |4 aut | |
| 700 | 1 | |a Fieschi, Franck |e verfasserin |4 aut | |
| 700 | 1 | |a Codée, Jeroen D C |e verfasserin |4 aut | |
| 700 | 1 | |a van Kooyk, Yvette |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in cell and developmental biology |d 2013 |g 8(2020) vom: 08., Seite 556 |w (DE-627)NLM240031415 |x 2296-634X |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2020 |g day:08 |g pages:556 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fcell.2020.00556 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2020 |b 08 |h 556 | ||